# US 2022/0088040 A1 · Use of System XC-Inhibitor for Treating Statin-Induced Myalgia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0088040 A1
- Document ID: US20220088040A1
- Status: Published application
- Kind: A1
- Application number: 16/755,631
- Filed: 2018-10-12
- Published: 2022-03-24
- Earliest claimed: 2017-10-13
- Assignees: Exerkine Corporation
- Applicants: Exerkine Corporation
- Inventors: Mark Tarnopolsky; Thomas Hawke
- Web page: https://patentgrep.com/patent/US20220088040A1

## CPC

- A61K 31/655: Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 31/145: having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2) (isothiourea A61K31/155)
- A61K 31/205: Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A61K 31/355: Tocopherols, e.g. vitamin E
- A61K 31/385: having two or more sulfur atoms in the same ring
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/51: Thiamines, e.g. vitamin B1
- A61K 31/525: Isoalloxazines, e.g. riboflavins, vitamin B2
- A61K 31/635: having a heterocyclic ring, e.g. sulfadiazine
- A61K 36/21: Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
- A61K 36/742: {Coffea, e.g. coffee}
- A61K 36/82: Theaceae (Tea family), e.g. camellia
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of reducing glutamate efflux from skeletal muscle by inhibiting system Xc- activity is provided. The method is useful for the treatment of statin-induced myalgia. Pharmaceutical compositions useful to treat statin-induced myalgia are also provided, as well as a kit.

## Claims

### Claim 1

A method of reducing glutamate efflux from muscle cells comprising the step of administering a system Xc- inhibitor to the cells.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The method of claim 1, wherein the system Xc- inhibitor is selected from the group consisting of: sulfasalazine, vitamin E, coenzyme Q10, cysteamine and combinations thereof.

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The method of claim 1, wherein glutamate efflux is reduced by at least about 25% of the glutamate efflux caused by statin administration.

### Claim 6 (depends on 3)

The method of claim 3, wherein sulfasalazine is administered at a dosage in the range of about 250 mg to about 5,000 mg; Vitamin E is administered at a dosage in the range of about 25 IU to about 2,500 IU; cysteamine is administered at a dosage in the range of about 150 mg to about 6,000 mg; and coenzyme Q10 is administered at a dosage in the range of about 25 mg to about 1,000 mg.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The method of claim 1, wherein the system Xc- inhibitor is administered in conjunction with a statin.

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The method of claim 1, wherein the second therapeutic agent is effective to treat muscle pain and is selected from the group of: non-steroidal anti-inflammatory agents, acetaminophen, tricyclic anti-depressants, anti-convulsants, selective serotonin reuptake inhibitors, and cannabinoids.

### Claim 11 (depends on 1)

The method of claim 1, wherein the second therapeutic agent is effective to treat mitochondrial dysfunction and is selected from the group of: antioxidants, mitochondrially targeted antioxidants, thiamine and riboflavin.

### Claim 12

A method of treating statin-induced myalgia in a mammal comprising the step of administering to the mammal a system Xc- inhibitor.

### Claim 13

(canceled)

### Claim 14 (depends on 12)

The method of claim 12, wherein the system Xc- inhibitor is selected from the group consisting of: sulfasalazine, vitamin E, coenzyme Q10, cysteamine and combinations thereof.

### Claim 15

(canceled)

### Claim 16 (depends on 12)

The method of claim 12, wherein the system Xc- inhibitor is administered in conjunction with a statin.

### Claim 17 (depends on 16)

The method of claim 16, wherein the system Xc- inhibitor is administered in conjunction with a second therapeutic agent.

### Claim 18 (depends on 16)

The method of claim 16, wherein the second therapeutic agent is effective to treat muscle pain and is selected from the group of: non-steroidal anti-inflammatory agents, acetaminophen, tricyclic anti-depressants, anti-convulsants, selective serotonin reuptake inhibitors, a muscle heating source, a muscle cooling source and cannabinoids, or the second therapeutic agent is effective to treat mitochondrial dysfunction and is selected from the group of: antioxidants, mitochondrially targeted antioxidants, thiamine and riboflavin.

### Claim 19

(canceled)

### Claim 20

A composition useful for treating statin-induced myalgia in a mammal comprising a system Xc- inhibitor in combination with i) one or more additional Xc-inhibitors; ii) a statin; or iii) a second therapeutic agent.

### Claim 21

(canceled)

### Claim 22 (depends on 20)

The composition of claim 20, wherein the system Xc- inhibitors are selected from the group consisting of: sulfasalazine, vitamin E, coenzyme Q10, cysteamine and combinations thereof.

### Claim 23 (depends on 20)

The composition as defined in claim 20, comprising a statin.

### Claim 24 (depends on 20)

The composition as defined in claim 20, comprising a second therapeutic agent.

### Claim 25 (depends on 24)

The composition of claim 24, wherein the second therapeutic agent is effective to treat muscle pain and is selected from the group of: non-steroidal anti-inflammatory agents, acetaminophen, tricyclic anti-depressants, anti-convulsants, selective serotonin reuptake inhibitors, and a cannabinoid, or the second therapeutic agent is effective to treat mitochondrial dysfunction and is selected from the group of: antioxidants, mitochondrially targeted antioxidants, thiamine and riboflavin.

### Claim 26

(canceled)

### Claim 27

A kit useful to treat statin-induced myalgia comprising a system Xc-inhibitor and a statin.

### Claim 28

(canceled)

### Claim 29 (depends on 12)

The method of claim 12, wherein the system Xc- inhibitor comprises a combination of vitamin E, coenzyme Q10, beet root extract, alpha lipoic acid and creatine.

### Claim 30 (depends on 20)

The composition of claim 20, comprising a combination of vitamin E, coenzyme Q10, beet root extract, alpha lipoic acid and creatine.
